Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
| ▸ | KCNK2 | O95069 | 2/20 | 0.30 |
| ▸ | KCNK10 | P57789 | 2/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17100897 | 0.80 | DHODH (0.39) | DHODHALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL17100734 | 0.80 | DHODH (0.39) | DHODHMEN1MAPTKMT2A | |
| SCHEMBL17100903 | 0.80 | DHODH (0.41) | DHODH | |
| SCHEMBL17100731 | 0.76 | DHODH (0.42) | DHODHMEN1MAPTKMT2A | |
| SCHEMBL28237511 | 0.76 | DHODH (0.52) | DHODHALDH1A1KIF11KCNK2KCNK10 | |
| SCHEMBL17100805 | 0.75 | DHODH (0.41) | DHODHALDH1A1MAPT | |
| SCHEMBL17100823 | 0.74 | DHODH (0.37) | DHODHMEN1MAPTKMT2A | |
| SCHEMBL17100845 | 0.73 | DHODH (0.36) | DHODHMEN1MAPTKMT2A | |
| SCHEMBL17100807 | 0.73 | DHODH (0.37) | DHODH | |
| SCHEMBL17100863 | 0.72 | DHODH (0.35) | DHODHALDH1A1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170088513-A1 | 2-CYANO-3-CYCLOPROPYL-3-HYDROXY-N-ARYL-THIOACRYLAMIDE DERIVATIVES | ALGIAX PHARMACEUTICALS GMBH (DE) | 2017-03-30 | — | — | US | claimed |
| EP-3119744-A1 | 2-CYANO-3-CYCLOPROPYL-3-HYDROXY-N-ARYL-THIOACRYLAMIDE DERIVATIVES | Algiax Pharmaceuticals GmbH (DE) | 2017-01-25 | — | — | EP | claimed |
| WO-2015140081-A1 | 2-CYANO-3-CYCLOPROPYL-3-HYDROXY-N-ARYL-THIOACRYLAMIDE DERIVATIVES | ALGIAX PHARMACEUTICALS GMBH (DE) | 2015-09-24 | — | — | WO | claimed |
| US-10472324-B2 | 2-cyano-3-cyclopropyl-3-hydroxy-N-aryl-thioacrylamide derivatives | ALGIAX PHARMACEUTICALS GMBH (DE) | 2019-11-12 | — | — | US | disclosed |
| US-20170088513-A1 | 2-CYANO-3-CYCLOPROPYL-3-HYDROXY-N-ARYL-THIOACRYLAMIDE DERIVATIVES | ALGIAX PHARMACEUTICALS GMBH (DE) | 2017-03-30 | — | — | US | disclosed |
| EP-3119744-A1 | 2-CYANO-3-CYCLOPROPYL-3-HYDROXY-N-ARYL-THIOACRYLAMIDE DERIVATIVES | Algiax Pharmaceuticals GmbH (DE) | 2017-01-25 | — | — | EP | disclosed |
| WO-2015140081-A1 | 2-CYANO-3-CYCLOPROPYL-3-HYDROXY-N-ARYL-THIOACRYLAMIDE DERIVATIVES | ALGIAX PHARMACEUTICALS GMBH (DE) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088513-A1 | 2-CYANO-3-CYCLOPROPYL-3-HYDROXY-N-ARYL-THIOACRYLAMIDE DERIVATIVES | GABRA3, GABRA2, GABRB3 | DHODH 3129/4885ALDH1A1 1076/4885KIF11 1769/4885 |
| US-10472324-B2 | 2-cyano-3-cyclopropyl-3-hydroxy-N-aryl-thioacrylamide derivatives | GABRA3, GABRA2, GABRB3 | DHODH 3129/4885ALDH1A1 1076/4885KIF11 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.